Merck's once weekly DPP-4 to personalize diabetes therapy
This article was originally published in Scrip
Executive Summary
Merck & Co. is keen to "individualize" and simplify therapy for type 2 diabetes patients, says Merck Research Laboratories' vice-president of late stage development for diabetes and endocrinology, Dr. Peter Stein, and its new once-weekly DPP-IV inhibitor omarigliptin is a key example of this.